Cell Therapeutics (CTIC) Receives EU Approval for Pixuvri as Monotherapy to Treat Relapsed/Aggressive Non-Hodgkin B-Cell Lymphomas

May 10, 2012 2:45 PM EDT Send to a Friend
Get Alerts CTIC Hot Sheet
Trade CTIC Now!
Join SI Premium – FREE
Cell Therapeutics (Nasdaq: CTIC) announces Pixuvri approved in EU as monotherapy to treat adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-Cell Lymphomas.

The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Hot Corp. News, Trading Halts

Add Your Comment